CorMedix Inc. (CRMD): Strong Sell On Partner Failure, Misleading Data And Paid Stock Promotion. -91.4% Downside by Pump Stopper
Also we are NOT an investment advisor but see some of our earlier articles on CRMD
[buffett]
Summary
- CRMD’s 1970s-era chemical acquired for <$1m cash from bankruptcy after 2+ failed sale attempts. Bankruptcy documents show Fresenius passed on CRMD even at <$2m value while Gambro deemed Taurolidine worthless.
- German corporate records show Tauropharm is ~$1.3-2.5m failure, indicating CRMD market claims are inaccurate. German court transcripts show CRMD patent based on “outdated” prior art view, so CRMD patent worthless.
- CRMD uses misleading clinical-data as in-depth industry research shows Neutrolin/Taurolidine is a failure while “40% benefit!” versus industry standards...
Login required to continue reading.
Setup a free account to get access to this article (no credit card required).
View Full ArticleAlready a member? Log in here
